

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/574,575
Applicant : Elena CONTI et al.
Filed : April 20, 2007
TC/A.U. : 1656
Examiner : Suzanne Marie Noakes
Docket No. : 2021-123
Customer No. : 6449
Confirmation No. : 9296

RESPONSE TO OFFICE ACTION RESTRICTION REQUIREMENT


Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

In response to an Office Action restriction requirement dated March 20, 2009,
Applicants elect Group IV, claim 9, with traverse. The restriction requirement is traversed
on the basis of the following.

It is asserted in the Office Action that claim 5 (Group II) is anticipated by Kufer et al.
Even if that is correct, without admitting same, at least the claims of Groups I and III share
the same special technical feature with elected claim 9, i.e., the 3-dimensional structural
information of the binding site of human TPX2 to phosphorylated human Aurora-A kinase.
Moreover, as the subject matter of the claims of Group V is a result of performing the
method of elected claim 9, Group V also shares the same special technical feature with
elected claim 9.

Respectfully submitted,

By 
George R. Repper
Registration No. 31,414
Attorney for Applicants
1425 K Street, N.W., Suite 800
Washington, D.C. 20005
Telephone No.: (202) 783-6040
Facsimile No.: (202) 783-6031